LMWH Infusion as Anticoagulation for Home HD

Status Recruiting

Clinical Trial Summary

There is a lack of data in the literature about the use of low-molecular weight heparin (LMWH) as anticoagulation for nocturnal home hemodialysis (NHHD). This study aims to evaluate the efficacy and safety of LMWH, administered by infusion method, as compared to unfractionated heparin as anticoagulation for NHHD treatment.

Clinical Trial Description

Low-molecular weight heparin (LMWH) and unfractionated heparin (UFH) are established systemic anticoagulants for the patients who receive conventional thrice-weekly hemodialysis in absence of significant bleeding risk. For the patients who undergo nocturnal home hemodialysis (NHHD), LMWH is seldom utilized because of the need of an additional bolus injection during a long dialysis treatment, which is impractical as the patients are sleeping during hemodialysis. Moreover, there is a potential risk of LMWH accumulation due to its longer half-life. As there is a paucity of data in the literature on the use of LMWH for NHHD treatment, this trial is conducted to assess the safety and efficacy of LMWH, administered by infusion method, in this particular group of dialysis patients. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02957877
Study type	Interventional
Source	Alice Ho Miu Ling Nethersole Hospital
Contact	Steve Siu-Man Wong, MBChB, FRCPC
Phone	(852) 26892000
Email	stevesmwong@gmail.com
Status	Recruiting
Phase	Phase 4
Start date	March 2016
Completion date	May 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03023748` - Intravenous Paricalcitol in Chronic Hemodialysis Patients	Phase 4
Terminated	`NCT00776191` - Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism	Phase 4
Completed	`NCT00745914` - Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients	N/A
Completed	`NCT02981706` - Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis	N/A
Completed	`NCT02946229` - Data Collection for Next Generation Ultrasound Technology Development	N/A
Completed	`NCT02976246` - Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients	Phase 4
Completed	`NCT02966028` - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)	Phase 2
Completed	`NCT00745719` - Parathyroidectomy in Endstage Renal Disease	N/A
Completed	`NCT03010072` - The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum	Phase 2
Recruiting	`NCT03020303` - Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease	Phase 3
Completed	`NCT00745589` - Sevelamer Hydrochloride in Peritoneal Dialysis Patients	N/A
Not yet recruiting	`NCT02976688` - Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis	Phase 2/Phase 3
Completed	`NCT02970201` - Improving Adherence in Renal Dialysis Patients Through Electronic Interventions	N/A
Withdrawn	`NCT00502268` - Vitamin D and Carboxy PTH Fragments in Coronary Calcification	Phase 4
Completed	`NCT02207153` - Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
Completed	`NCT02977117` - The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis	Phase 2
Completed	`NCT02866214` - Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.	Phase 2/Phase 3
Not yet recruiting	`NCT03054454` - A Podiatry Led MDT Intervention to Reduce the Burden of Foot Disease in Patients With End Stage Kidney Failure	N/A